Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 16,201 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active-Control Clear all
Completed Phase 4 Interventional Results available

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

NCT02827500
View directory record Official record
Conditions
Heart Failure
Interventions
ivabradine, Usual Care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
20
States / cities
Aurora, Colorado • Fort Lauderdale, Florida • Athens, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion

NCT06820736
View directory record Official record
Conditions
Complications, Postoperative
Interventions
Drain
Device
Lead sponsor
Twin Cities Spine Center
Other
Eligibility
18 Years to 70 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gevokizumab for Active Scleritis

NCT01835132
View directory record Official record
Conditions
Scleritis
Interventions
Gevokizumab
Device
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Selecting Effective Combinations of Treatment for Low Back Pain

NCT03520387
View directory record Official record
Conditions
Low Back Pain
Interventions
Lumbar medial branch nerve radiofrequency ablation (LRFA), Simulated LRFA with targeted steroid injections, AcTIVE-CBT, TBSCE
Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)

NCT05013905
View directory record Official record
Conditions
Crohn Disease
Interventions
Tulisokibart, Companion Diagnostic (CDx)
Biological · Diagnostic Test
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
16
States / cities
Los Angeles, California • Liberty, Kansas • Chesterfield, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder

NCT05974202
View directory record Official record
Conditions
Cocaine Use, Cocaine Dependence, Cocaine Use Disorder, Cocaine Use Disorder, Moderate, Cocaine Use Disorder, Severe
Interventions
Active H7-coil repetitive transcranial magnetic stimulation (rTMS), Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
22 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Not applicable Interventional

MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression

NCT05220202
View directory record Official record
Conditions
Chronic Back Pain, Depression, Aging, Musculoskeletal Pain
Interventions
Behavioral Intervention Group (MOTIVATE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 99 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Low Intensity Ultrasound Neuromodulation of Repetitive Negative Thinking In Depression

NCT05697172
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low-intensity focused ultrasound
Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

NCT04999839
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
NDI-034858 study drug, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
59
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Poweroff Sleep Study

NCT03364101
View directory record Official record
Conditions
Sleep
Interventions
Placebo Capsule, POWEROFF Capsule
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 27, 2026, 10:37 PM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), Placebo, LOU064 (open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
43
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Not applicable Interventional

Pilates+4MS: Pilates Intervention for Multiple Sclerosis

NCT06300619
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Pilates+4, Pilates
Behavioral
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Not applicable Interventional

The DETECT HCV Linkage to Care Trial

NCT04026867
View directory record Official record
Conditions
Hepatitis C
Interventions
Linkage Navigation, Clinician Referral
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Benralizumab for Eosinophilic Gastritis (BEGS)

NCT03473977
View directory record Official record
Conditions
Eosinophilic Gastritis or Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 27, 2026, 10:37 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

NCT04925557
View directory record Official record
Conditions
Secondary-progressive Multiple Sclerosis
Interventions
Mayzent, Ocrevus
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 27, 2026, 10:37 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

NCT07360301
View directory record Official record
Conditions
Well-Being, Psychological, Psychedelic Experiences
Interventions
Psilocybin, Saline Placebo, Clonidine
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Based Treatment for Weight Loss With Breakfast Prescription

NCT02467036
View directory record Official record
Conditions
Obesity, Overweight, Overeating, Weight, Childhood Obesity
Interventions
Family Based Behavioral Treatment
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
8 Years to 12 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

NCT00240929
View directory record Official record
Conditions
-Unhealthy Children With a History of Prematurity
Interventions
MEDI-493
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Months to 6 Months
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

Feasibility/Acceptability of Attentional-Control Training in Survivors

NCT05528939
View directory record Official record
Conditions
Pediatric Cancer, Pediatric ALL, Pediatric Brain Tumor, Attention Difficulties, Cognitive Deficit in Attention
Interventions
EndeavorRx, Control video game
Device · Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

NCT07285057
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

NCT06863467
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Interventions
Intravenous Gemini, Intravenous placebo
Drug
Lead sponsor
Revelation Biosciences, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Chula Vista, California • La Mesa, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 27, 2026, 10:37 PM EDT